Investigation on the Effectivity of Management of Clinical Pathway in Type 2 Diabetes Patients

宁帆,曾文衡,汤珂珂,吴箐,谷卫

DOI: https://doi.org/10.3969/j.issn.1009-816x.2010.02.006

2010-01-01

Abstract:Objective To observe the effect of the clinical management pathway on the glycemic control and pancreatic β cell function in type 2 diabetes patients.Methods An open controlled reality research method was adopted in this study.According to CDS guideline,107 Outpatients with type 2 diabetes were divided into two groups.Group A:BMI≥24Kg/m2,metformin plus insulin sensitizer agent was used,and group B:BMI≤24Kg/m2,metformin plus insulin secretion promoting agents was used.The average follow-up was 1.5 years.The fasting blood glucose (FBG),2 hours postprandial blood glucose (2hPBG),glycosylated hemoglobin A1c (HbA1c),fasting insulin (FINS),2 hours postprandial insulin (2hINS)、serum lipids (TG,LDL-C,and HDL-C),HOMA-IR,HOMA-IS,and HOMA-IAI were compared between before (baseline) and after treatment for two groups.Results Compared to baseline,the levels of FBG、2hPBG、HbA1c were decreased significantly in both group A and B (P0.05).The rate of good HbA1c control (HbA1c value 6.5%) was significantly increased (70.37% vs 55.5% in group A,65.96% vs 48.94% in group B,respectively).HOMA-IAI were significantly increased(P0.05)while HOMA-IR decreased (P0.05) in Group A.HOMA-IAI and HOMA-IS were significantly increased while HOMA-IR decreased (P0.05～0.01) in Group B.Conclusions The rates of good control in HbA1c and pancreatic β cell function were significantly improved in patients with type 2 diabetes mellitus under the management of clinical pathway.